Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) announced on Thursday that it has enrolled its first US patient for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of the COVID-19 coronavirus. 26 patients in total have been brought together and Company CEO Christopher J. Moreau expects to reach 25% of the total target shortly.
To learn more about this trial,
click here.
The Clinical stage pharmaceutical development Company
recently reported that the first patient had been dosed in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug Ifenprodil. The patient was enrolled and dosed at the Waikato Hospital located in Hampton, New Zealand. The drug Ifenprodil has been shown to - “mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of IPF."
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.